Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

• Published in: World journal of surgical oncology 2023-06, Vol.21 (1), p.194-194, Article 194
• Main Authors: Chen, Xuanzhao, Li, Zeyan, Liang, Meihua, Zhang, Ziyang, Zhu, Di, Lin, Biyun, Zhou, Renyu, Lu, Yuanzhi
• Format: Article
• Language: English
• Subjects: Analysis; Androgens; Apoptosis; Bioinformatics; Biomarkers; Breast cancer; Cancer; Cancer therapies; Cell activation; Cell Cycle; Chemotherapy; Clinical trials; Data analysis; Data mining; DNA damage; DNA polymerase; Doxorubicin; Gene expression; Gene sequencing; Genes; Genomes; Humans; Immune checkpoint; Immune microenvironment; Immune system; Immunotherapy; Medical prognosis; Metabolism; Metastases; Microenvironments; Mutation; Patient outcomes; Patients; Prognosis; Ribonucleic acid; RNA; RNA sequencing; Survival; Targeting therapy; Therapeutic applications; Therapeutic targets; TNBC; Transcription Factors - genetics; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Tumor Microenvironment; Tumor-infiltrating lymphocytes
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-023-03078-7

Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and targets for patient stratification and treatment of TNBC are urgently needed. It has been reported that the overexpression of DNA damage-inducible transcript 4 gene (DDIT4) is associated with resistance to neoadjuvant chemotherapy and poor prognosis in patients with TNBC. In this study, we aimed to identify novel biomarkers and therapeutic targets using RNA sequencing (RNA-seq) and data mining using data from public databases. RNA sequencing (RNA-Seq) was performed to detect the different gene expression patterns in the human TNBC cell line HS578T treated with docetaxel or doxorubicin. Sequencing data were further analyzed by the R package "edgeR" and "clusterProfiler" to identify the profile of differentially expressed genes (DEGs) and annotate gene functions. The prognostic and predictive value of DDIT4 expression in patients with TNBC was further validated by published online data resources, including TIMER, UALCAN, Kaplan-Meier plotter, and LinkedOmics, and GeneMANIA and GSCALite were used to investigate the functional networks and hub genes related to DDIT4, respectively. Through the integrative analyses of RNA-Seq data and public datasets, we observed the overexpression of DDIT4 in TNBC tissues and found that patients with DDIT4 overexpression showed poor survival outcomes. Notably, immune infiltration analysis showed that the levels of DDIT4 expression correlated negatively with the abundance of tumor-infiltrating immune cells and immune biomarker expression, but correlated positively with immune checkpoint molecules. Furthermore, DDIT4 and its hub genes (ADM, ENO1, PLOD1, and CEBPB) involved in the activation of apoptosis, cell cycle, and EMT pathways. Eventually, we found ADM, ENO1, PLOD1, and CEBPB showed poor overall survival in BC patients. In this study, we found that DDIT4 expression is associated with the progression, therapeutic efficacy, and immune microenvironment of patients with TNBC, and DDIT4 would be as a potential prognostic biomarker and therapeutic target. These findings will help to identify potential molecular targets and improve therapeutic strategies against TNBC.